JavaScript seems to be disabled in your browser. For the best experience on our site, be sure to turn on Javascript in your browser.

Home
Signaling Pathways

Signaling Pathways

A8236 Regorafenib
4 Citation

Target: Raf|VEGFR|PDGFR|c-Kit|RET

Summary: Inhibitor of VEGFR/PDGFR/FGFR/mutant kit/RET/Raf-1

≥25.04 mg/mL
A8252 Nintedanib (BIBF 1120)
3 Citation

Target: VEGFR|PDGFR|FGFR

Summary: VEGFR/PDGFR/FGFR inhibitor

insoluble in H2O; insoluble in EtOH; ≥5.34 mg/mL
A2942 Masitinib (AB1010)

Target: PDGFR|c-Kit|Lyn

Summary: Tyrosine kinase inhibitor, potent and selective

≥24.95 mg/mL
A2168 Dovitinib (TKI-258, CHIR-258)
2 Citation

Target: FLT3|VEGFR|PDGFR|c-Kit|FGFR

Summary: Multitargeted RTK inhibitor

insoluble in H2O; insoluble in EtOH; ≥36.35 mg/mL
A2412 CP-724714

Target: VEGFR|PDGFR|Bcr-Abl|Src|EGFR|c-MET|Insulin Receptors|IRG-1R

Summary: HER2 inhibitor,potent and selective

≥23.5 mg/mL
A2174 Lenvatinib (E7080)

Target: VEGFR|PDGFR|RET

Summary: VEGFR inhibitor

≥21.35 mg/mL
A5467 Ponatinib (AP24534)
1 Citation

Target: VEGFR|PDGFR|Bcr-Abl|FGFR|Src

Summary: pan-BCR-ABL inhibitor,multi-kinase inhibitor

≥53.3 mg/mL
A2477 Tyrphostin AG 1296
1 Citation

Target: PDGFR

Summary: PDGFR inhibitor,selective and ATP-competitive
A8307 Crenolanib (CP-868596)
1 Citation

Target: FLT3|PDGFR

Summary: PDGFR-β inhibitor,potent and selective

≥22.2 mg/mL
A8370 Axitinib (AG 013736)
1 Citation

Target: VEGFR|PDGFR|c-Kit

Summary: VEGFR1/ c-Kit inhibitor

insoluble in H2O; ≥19.3 mg/mL